Skip to content

Immunomedics started at buy by Cowen

May 26, 2017

Cowen initiates coverage on Immunomedics (NASDAQ: IMMU) with a Outperform rating and a price target of $15.00.

Analyst Dr. Phil Nadeau comments “Immunomedics’ lead candidate IMMU-132 has produced compelling Ph. II data in
the treatment of relapsed/refractory mTNBC and our physician consultants expect IMMU-132 to become part of the standard of care. We project a FY2019 launch, and that IMMU-132 will achieve $720MM in worldwide revenue in mTNBC by 2025.”

FY 2017 EPS estimate is for a loss of $1.10 and FY 2018 EPS estimate is for a loss of $0.70.

http://bit.ly/2r3NUJq

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: